Patents Represented by Attorney Hannah O. Green
-
Patent number: 5175165Abstract: The present invention relates to novel ribonucleotide reductase inhibitors and new combinations comprising an antiviral compound, such as acyclovir, and a thiocarbonohydrazone ribonucleotide reductase inhibitor for the chemotherapeutic treatment of virus infections, espectially viruses of the herpes group.Type: GrantFiled: June 26, 1989Date of Patent: December 29, 1992Assignee: Burroughs Wellcome Co.Inventors: Todd A. Blumenkopf, Thomas Spector, Devron R. Averett, Robert W. Morrison, Jr., Eric C. Bigham, Virgil L. Styles
-
Patent number: 5166160Abstract: The present invention is concerned with the compound of formula (I) ##STR1## and its acid addition salts. The invention is also directed to the use of the compound of formula (I) and its pharmaceutically acceptable acid addition salts as positive conotropic agents in mammals.Type: GrantFiled: August 11, 1988Date of Patent: November 24, 1992Assignee: Burroughs Wellcome Co.Inventor: Arthur P. Phillips
-
Patent number: 5153318Abstract: The present invention relates to 3'-azido purine nucleosides and their use in medical therapy, particularly for the treatment of human immunodeficiency virus and hepatitis B virus infections, to methods for their preparation and to compositions containing them.Type: GrantFiled: October 2, 1990Date of Patent: October 6, 1992Assignee: Burroughs Wellcome Co.Inventors: Janet L. Rideout, George A. Freeman, Steven A. Short, Merrick R. Almond, Jon L. Collins
-
Patent number: 5104870Abstract: Novel (2S, 3S, 5R) morpholinols of formula (I) ##STR1## together with the (+-)-(2R*,3R*,5S*) racemates thereof, and their salts, whereinX is hydrogen, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or a group --CH.sub.2 --X.sup.1 where X.sup.1 is cycloalkyl of 3 to 6 carbon atoms.The compounds have a variety of uses in human medicine, in particular in the treatment of mental disorders such as depression.Type: GrantFiled: April 2, 1991Date of Patent: April 14, 1992Assignee: Burroughs Wellcome Co.Inventors: James L. Kelley, David L. Musso, Grady E. Boswell, Barrett R. Cooper
-
Patent number: 5104897Abstract: A class of halogen-substituted diphenylsulfide compounds are disclosed which produce a large selective inhibition of serotonin uptake in brain. Such compounds are useful in the treatment of depression, anxiety, obsessive compulsive disorders and substance abuse disorders such as alcoholism.Type: GrantFiled: June 28, 1991Date of Patent: April 14, 1992Assignee: Burroughs Wellcome Co.Inventors: Lawrence E. Brieaddy, Claudia E. B. Hollingsworth, Barrett R. Cooper
-
Patent number: 5102914Abstract: The present invention is concerned with compounds of formula (I) ##STR1## wherein R.sub.1 is hydrogen;R.sub.2 is carbonyl; andR.sub.3 is hydroxy;and salts thereof, with processes for preparing same and with their use in medicine for the treatment of hypertension.Type: GrantFiled: December 18, 1989Date of Patent: April 7, 1992Assignee: Burroughs Wellcome Co.Inventors: John D. McDermed, Anjaneyulu S. Tadepalli, Vincent H. Chang, Kevin P. Hurley
-
Patent number: 5095039Abstract: A halogen-substituted diphenylsulfide compound is disclosed which produce a large selective inhibition of serotonin uptake in brain. This compound is useful in the treatment of depression as well as anxiety, obsessive compulsive disorders and alcoholism.Type: GrantFiled: June 5, 1990Date of Patent: March 10, 1992Assignee: Burroughs Wellcome Co.Inventors: Nariman B. Mehta, Lawrence E. Brieaddy
-
Patent number: 5089500Abstract: The present invention relates to 6-substituted purine carbocyclic nucleosides and their use in medical therapy particularly in the treatment of HIV and HBV infections. Also provided are pharmceutical formulations and processes for the preparation of compounds according to the invention.Type: GrantFiled: May 8, 1991Date of Patent: February 18, 1992Assignee: Burroughs Wellcome Co.Inventor: Susan M. Daluge
-
Patent number: 5087697Abstract: The present invention relates to 6-substituted purine carbocyclic nucleosides and their use in medical therapy particularly in the treatment of HIV and HBV infections. The invention also relates to pharmaceutical formulations and processes for the preparation of compounds according to the invention.Type: GrantFiled: December 19, 1990Date of Patent: February 11, 1992Assignee: Burroughs Wellcome Co.Inventor: Susan M. Daluge
-
Patent number: 5071983Abstract: This invention relates to certain derivatives of 2', 3'-dideoxycytidine and their use in medical therapy particularly in the treatment of HIV infections. Also provided are pharmaceutical formulations and processes for the manufacture of the compounds according to the invention.Type: GrantFiled: October 6, 1989Date of Patent: December 10, 1991Assignee: Burroughs Wellcome Co.Inventors: George W. Koszalka, Thomas A. Krenitsky
-
Patent number: 5070078Abstract: 2',3'-Dideoxy-3'-fluoro pyrimidine nucleosides particularly 2',3'-dideoxy-3'-fluorothymidine have been found to have particularly potent activity against adenovirus infections especially those caused by adenoviruses of serotype 8. Such compounds are preferably presented in pharmaceutical formulations adapted for ophthalmic administration.Type: GrantFiled: August 19, 1988Date of Patent: December 3, 1991Assignee: Burroughs Wellcome Co.Inventors: John W. T. Selway, Lowrie M. Beacham, III, Susan M. Daluge, Joel Van Tuttle, Thomas A. Krenitsky
-
Patent number: 5068320Abstract: This invention relates to certain 6-substituted 2',3'-dideoxypurine nucleosides and derivatives thereof. The compounds are useful as antivirals.Type: GrantFiled: October 6, 1989Date of Patent: November 26, 1991Assignee: Burroughs Wellcome Co.Inventors: George W. Koszalka, Charlene L. Burns, Thomas A. Krenitsky, Janet L. Rideout
-
Patent number: 5061708Abstract: The present invention relates to certain amino acid esters of the purine nucleoside acyclovir, pharmaceutically acceptable salts thereof and their use in the treatment and prophylaxis of herpes virus infections. The invention also includes pharmaceutical formulations and processes for the preparation of such compounds.Type: GrantFiled: November 21, 1989Date of Patent: October 29, 1991Assignee: Burroughs Wellcome Co.Inventor: Thomas A. Krenitsky
-
Patent number: 5049671Abstract: The present invention relates to 6-substituted purine carbocyclic nucleosides and their use in medical therapy particularly in the treatment of HIV and HBV infections. Also provided are pharmaceutical formulations and processes for the preparation of compounds according to the invention.Type: GrantFiled: December 22, 1989Date of Patent: September 17, 1991Assignee: Burroughs Wellcome Co.Inventor: Susan M. Daluge
-
Patent number: 5049581Abstract: The present invention relates to compounds of formula(I) ArCh.sub.Type: GrantFiled: August 25, 1989Date of Patent: September 17, 1991Assignee: Burroughs Wellcome Co.Inventor: Kenneth W. Bair
-
Patent number: 5043339Abstract: The present invention relates to amino acid esters of pyrimidine and purine nucleosides containing an acyclic side chain, and their use in medical therapy, particularly the treatment of herpes virus infections. Also provided are pharmaceutical formulations and processes for the preparation of compounds according to the invention.Type: GrantFiled: December 18, 1989Date of Patent: August 27, 1991Assignee: Burroughs Wellcome Co.Inventor: Lilia M. Beauchamp
-
Patent number: 5041543Abstract: A compound 1-(3-azido-2,3-dideoxy-.beta.-D-erythro-pentofuranoxyl)-5-methyl-2(1H)-pyr imidinone and its use in a method of generating (forming, providing) 3'-azido-3'-deoxythymidine (zidovudine sometimes referred to as AZT) in the body of an animal (a mammal such as human) by systemically administering 1-(3-azido-2,3-dideoxy-.beta.-D-erythro-pentofuranosyl)-5-methyl-2(1H)-pyr iminone to said animal (mammal such as a human) is disclosed. AZT is approved and used for treating HIV infections, e.g., AIDS and ARC in humans and also has activity against gram-negative bacteria in animals.Type: GrantFiled: September 16, 1988Date of Patent: August 20, 1991Assignee: Burroughs Wellcome Co.Inventors: Sammy R. Shaver, George A. Freeman, Janet L. Rideout
-
Patent number: 5034394Abstract: The present invention relates to 6-substituted purine carbocyclic nucleosides and their use in medical therapy particularly in the treatment of HIV and HBV infections. Also provided are pharmaceutical formulations and processes for the preparation of compounds according to the invention.Type: GrantFiled: December 22, 1989Date of Patent: July 23, 1991Assignee: Burroughs Wellcome Co.Inventor: Susan M. Daluge
-
Patent number: 5021437Abstract: The present invention relates to a novel ribonucleotide reductase inhibitor and new combinations comprising an antiviral compound, such as acyclovir, and a thiocarbonohydrazone ribonucleotide reductase inhibitor for the chemotherapeutic treatment of virus infections, especially viruses of the herpes group.Type: GrantFiled: June 26, 1989Date of Patent: June 4, 1991Assignee: Burroughs Wellcome Co.Inventor: Todd A. Blumenkopf
-
Patent number: 5019577Abstract: The present invention provides a compound selected from:N-[4-(3 -(2,4-diamino-1,6-dihydro-6-oxo-5-pyrimidinyl)propylamino)-2-flurobenzoyl] -(L)-glutamic acid,N-[4-( 3-(2,4-diamino-1,6-dihydro-6-oxo-5-pyrimidinyl)propylamino)-3-flurobenzoyl ]-(L)-glutamic acid,N-[4 -(3 -(2,4-diamino-1,6-dihydro-6-oxo-5-pyrimidinyl)propylamino)-3-methylbenzoyl ]-(L)-glutamic acid,N-[4-( 2,4-diamino-1,6-dihydro-6-oxo-5-pyrimidinyl)propylamino)-3-(methoxy)benzoy l](L)-glutamic acid andN-[4-(3 -(2,4-diamino-1,6-dihydro-6-oxo-5-pyrimidinyl)propylamino)-2-chlorobenzoyl ](L)-glutamic acid,or a salt thereof, methods for the preparation of the compounds, intermediates in their preparations, pharmaceutical formulations containing them, and their use in the treatment of tumors.Type: GrantFiled: April 15, 1988Date of Patent: May 28, 1991Assignee: Burroughs Welcome Co.Inventor: Eric C. Bigham